المصدر: Choline-PET: Exploratory Study Assessing the Potential Role of F-choline PET Imaging in New and Emerging Indications

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04999215Test

المساهمون: Murielle Surquin, Head of the Internal Medicine and Geriatrics Department

المصدر: Sanchez-Rodruez D, Marco E, Davalos-YerovV, Lopez-Escobar J, MessaggSartor M, Barrera C, Ronqulo-Moreno N, Vazquez-ar O, Calle A, zarM, Ptrowz K, Duran X, Escalada F, Munsa JM, Duarte E. Translatn and Valatn of the Spanh Versn of the SARC-F Questnnae to Assess Sarcopen Older People. J Nutr Health Agg. 2019;23(6):518-524. do 10.1007/s12603-019-1204-z.
Ptrowz K, Gluszewska A, Czesak J, Fedyk-Lukas M, Klek E, Sanchez-Rodruez D, Skalska A, Gryglewska B, GrodzkT, GasowskJ. SARC-F as a case-fdg tool for sarcopen accordg to the EWGSOP2. Natnal valatn and comparon wh other dgnost standards. Agg Cl Exp Res. 2021 Jul;33(7):1821-1829. do 10.1007/s40520-020-01782-y. Epub 2021 Jan 28.
Sanchez-Rodruez D, Marco E, Cruz-Jentoft AJ. Defg sarcopen: some caveats and challenges. Curr Op Cl Nutr Metab Care. 2020 Mar;23(2):127-132. do 10.1097/MCO.0000000000000621.
Cruz-Jentoft AJ, Bahat G, Bauer J, Bo Y, Bruyere O, Cederholm T, Cooper C, LandF, Rolland Y, Sayer AA, Schneer SM, Sber CC, Topkova E, Vandewoude M, Vser M, ZambonM; Wrg Group for the European Workg Group on Sarcopen Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopen: reved European consensus on defn and dgnos. Age Ageg. 2019 Jan 1;48(1):16-31. do 10.1093/ageg/afy169. Erratum : Age Ageg. 2019 Jul 1;48(4):601.
Performance Indicators of the SARC-F Questionnaire in Acute Care

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04757454Test

المصدر: Pilot Study Evaluating the Uptake of [18F] F-GLN by PET/CT in Breast Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03863457Test

المصدر: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05076149Test

المصدر: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04058353Test

المؤلفون: Dublin City University, Enterprise Ireland

المصدر: Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, Gulmezoglu AM, Temmerman M, Alkema L. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014 Jun;2(6):e323-33. doi: 10.1016/S2214-109X(14)70227-X. Epub 2014 May 5.
Gong JM, Shen Y, He YX. Reference Intervals of Routine Coagulation Assays During the Pregnancy and Puerperium Period. J Clin Lab Anal. 2016 Nov;30(6):912-917. doi: 10.1002/jcla.21956. Epub 2016 Apr 7.
Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, Sibony O, Mahieu-Caputo D, Hurtaud-Roux MF, Huisse MG, Denninger MH, de Prost D; PPH Study Group. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost. 2007 Feb;5(2):266-73. doi: 10.1111/j.1538-7836.2007.02297.x. Epub 2006 Nov 6.
A Clinical Study to Define Precision, Accuracy, and Comparability of Results From a Novel Point of Care Fibrinogen Assay (F-Point), Compared to an Industry Standard

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03623061Test

المصدر: Cederholm T, Bosaeus BarazzonR, Bauer J, Van Gossum A, Klek S, MuscarolM, Nyulas Ockenga J, Schneer SM, de van der Schueren MA, Sger P. Dgnost crer for malnutrn - An ESPEN Consensus Statement. Cl Nutr. 2015 Jun;34(3):335-40. do 10.1016/j.clnu.2015.03.001. Epub 2015 Mar 9.
Dellre S, Cynober L. transthyret a good marker of nutrnal status? Cl Nutr. 2017 Apr;36(2):364-370. do 10.1016/j.clnu.2016.06.004. Epub 2016 Jun 20.
ZambonM, MazzalG, Fant F, RossA, DFrancesco V. Sarcopen obesy: a new category of obesy the elderly. Nutr Metab Cardvasc D. 2008 Jun;18(5):388-95. do 10.1016/j.numecd.2007.10.002. Epub 2008 Apr 18.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Bo Y, Cederholm T, LandF, Mart FC, Mhel JP, Rolland Y, Schneer SM, Topkova E, Vandewoude M, ZambonM; European Workg Group on Sarcopen Older People. Sarcopen: European consensus on defn and dgnos: Report of the European Workg Group on Sarcopen Older People. Age Ageg. 2010 Jul;39(4):412-23. do 10.1093/ageg/afq034. Epub 2010 Apr 13.
Beaudart C, Zaar M, Pasleau F, Regster JY, Bruyere O. Health Outcomes of Sarcopen: A Systemat Revw and Meta-Analys. PLoS One. 2017 Jan 17;12(1):e0169548. do 10.1371/journal.pone.0169548. eCollectn 2017.
Deren ME, Babu J, Cohen EM, Machan J, Born CT, Hayda R. creased Mortaly Elderly Patnts wh Sarcopen and Acetabular Fractures. J Bone Jot Surg Am. 2017 Feb 1;99(3):200-206. do 10.2106/JBJS.16.00734.
Ethgen O, Beaudart C, Buckx F, Bruyere O, Regster JY. The Future Prevalence of Sarcopen Europe: A Cla for Publ Health Actn. Calc Tsue t. 2017 Mar;100(3):229-234. do 10.1007/s00223-016-0220-9. Epub 2016 Dec 24.
Malmstrom TK, Mler DK, Sonsk EM, FerruccL, Morley JE. SARC-F: a symptom score to predt persons wh sarcopen at rk for poor functnal outcomes. J Cachex Sarcopen Muscle. 2016 Mar;7(1):28-36. do 10.1002/jcsm.12048. Epub 2015 Jul 7.
Charlson ME, PompeP, Ales KL, MacKenz CR. A new method of classyg prognost comorby longudal studs: development and valatn. J Chron D. 1987;40(5):373-83. do 10.1016/0021-9681(87)90171-8.
Evaluation of the SARC-F Score as a Screening Tool for Undernutrition in a Geriatric Population

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03553147Test

المصدر: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03525548Test

المصدر: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03460990Test

المصدر: Clinical Study to Compare Clinical Outcomes of IOLs FineVision POD F GF (Hydrophobic) and FineVision POD F (Hydrophilic) After Bilateral Implantation in Asian Eyes

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03306355Test